Sai Life Sciences gains on inking pact to acquire land along with certain building structures in Shamirpet
Sai Life Sciences is currently trading at Rs. 654.70, up by 3.30 points or 0.51% from its previous closing of Rs. 651.40 on the BSE.
The scrip opened at Rs. 648.65 and has touched a high and low of Rs. 662.10 and Rs. 648.50 respectively. So far 4028 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 808.20 on 26-Dec-2024 and a 52 week low of Rs. 647.95 on 27-Jan-2025.
Last one week high and low of the scrip stood at Rs. 716.50 and Rs. 647.95 respectively. The current market cap of the company is Rs. 13661.79 crore.
The promoters holding in the company stood at 35.24%, while Institutions and Non-Institutions held 23.67% and 41.09% respectively.
Sai Life Sciences has entered into a long-term lease agreement for acquiring an area of 1.21 acres of land along with certain building structures in Shamirpet, Hyderabad at an upfront investment of around Rs 15 crore. The company plans to create R&D facility on the said leased land which will augment the existing Unit II Hyderabad Facility. The said investment will be funded from internal accruals. The proposed facility is expected to be partially operational in Q4 of financial year ending March 2026.
Sai Life Sciences is a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. It provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms.
